Introduction {#Sec1}
============

Firefighting is known to be a high-risk occupation. The International Agency for Research on Cancer (IARC) rated occupational exposure as a firefighter as possibly carcinogenic to humans (Group 2B) (International Agency for Research on Cancer (IARC) [@CR39]). Firefighters are exposed to numerous carcinogens during fire suppression, but also at the fire stations. They are exposed to diesel engine exhaust if vehicles are run in closed halls or without appropriate ventilation systems (International Agency for Research on Cancer (IARC) [@CR39]; Bott et al. [@CR15]; Froines et al. [@CR27]). At the fire scene, toxic and carcinogenic substances including metals, chemical substances, minerals, and various gases are released during combustion. The resulting fire smoke is a variable mixture of compounds and its toxicity varies greatly as every burning condition and burning material induces a unique pattern (Golka and Weistenhöfer [@CR31]; Guidotti and Clough [@CR33]).

Some meta-analyses have examined the extent of cancer risk among firefighters before and did not find higher overall cancer incidence and mortality as expected (International Agency for Research on Cancer (IARC) [@CR39]; Jalilian et al. [@CR40]; Sritharan et al. [@CR62]; Crawford et al. [@CR20]; LeMasters et al. [@CR44]; Youakim [@CR67]; Howe and Burch [@CR38]), although a few single studies reported elevated overall cancer risks (Daniels et al. [@CR21]; Glass et al. [@CR29]; Guidotti [@CR32]; Pukkala et al. [@CR58]). However, meta-analyses found that firefighters were at increased risk of developing or dying from malignant melanoma of the skin (Jalilian et al. [@CR40]; Howe and Burch [@CR38]), multiple myeloma (LeMasters et al. [@CR44]), mesothelioma (Jalilian et al. [@CR40]), digestive (Jalilian et al. [@CR40]; LeMasters et al. [@CR44]), prostate (Jalilian et al. [@CR40]; LeMasters et al. [@CR44]; Sritharan et al. [@CR62]), testicular (Jalilian et al. [@CR40]; LeMasters et al. [@CR44]), kidney (Youakim [@CR67]), bladder (Jalilian et al. [@CR40]), and thyroid cancer (Jalilian et al. [@CR40]), as well as non-Hodgkin lymphoma (Jalilian et al. [@CR40]; Youakim [@CR67]; LeMasters et al. [@CR44]).

Findings among these studies have been generally inconsistent. Reasons for this might be the lack of included non-occupational risk factors, missing specification of the exposure, period effects, and country-specific differences. All of these meta-analyses did not consider changes over time of firefighting technology, personal protective equipment (PPE), or used materials in buildings, furniture, or vehicles, which might have led to different cancer risks over the past decades. Combustion and pyrolysis products from newer building materials and furnishings (particularly polymers) are believed to be more toxic than smoke from fires in buildings built before these materials were widely used (Alarie [@CR3]). It has been shown in a series of experimental fire tests that the highest pollutant concentrations resulted from the combustion of polymeric materials (Reisen et al. [@CR60]). Polymers have been used in large amounts in Europe and North America since the 1950s (Guidotti and Clough [@CR33]; Alarie [@CR3]; Pedersen et al. [@CR56]). However, the other studies showed that the composition of the smoke produced by fires of various kinds was similar (Austin et al. [@CR7], [@CR8]).

In the past, PPE of firefighters changed tremendously. The use of modern self-contained breathing apparatus (SCBA) started during the 1960s and 1970s (Misner et al. [@CR50]), and is commonly used today by municipal firefighters, although they are not worn during the whole firefighting activity especially during overhaul (International Agency for Research on Cancer (IARC) 2010; Austin et al. [@CR6]). In the 1980s, modern firefighting helmets like the F1 helmet and advanced fire and heat resistant suits were introduced (Pedersen et al. [@CR56]; Hasenmeier [@CR35]). The cancer risk in firefighters may also vary between different geographical areas because of probably different exposure patterns depending on work activities and PPE (Howe and Burch [@CR38]; Moher et al. [@CR51]).

The purpose of this study was to compare cancer risks among professional firefighters from different decades and different geographic areas (North America, Europe, and Korea/Australia/New Zealand) under the assumption that firefighting cancer risks differ in the time course and between geographical areas.

Materials and methods {#Sec2}
=====================

Search strategy and inclusion criteria {#Sec3}
--------------------------------------

In March 2019, we searched the PubMed database to identify peer-reviewed original research articles available in English language about cancer risk and firefighting published until 31th December 2018 in accordance with Preferred Reporting Items for Systematic Reviews and MetaAnalyses (PRISMA) (Moher et al. [@CR51]). The search string, following the search term from Jalilian et al. ([@CR40]), includes keywords for targeting the occupation (firefighter) and the outcome (cancer incidence or cancer mortality) is presented in Supplemental Table S1. Only articles reporting cohort studies with standardized incidence ratios (SIRs) or standardized mortality ratios (SMRs) regarding the general population as reference or case--control studies were eligible for this meta-analysis. Data extraction was performed by one author (SC) and checked by another (DT). Both authors examined the abstracts independently and agreed on the studies to be included in the meta-analysis.

The PubMed search yielded 601 articles. Additionally, the reference lists of all appropriate articles were reviewed for pertinent studies that may have been missed in the search resulting in 16 additional records. Cohort studies that examine volunteers (Glass et al. [@CR30]), WTC-exposed firefighters (Zeig-Owens et al. [@CR70]), or veterans (Blair et al. [@CR14]) were excluded from the analyses because of possible different exposure patterns, less attended incidents, and the proposed healthy-volunteer effect. Case--control studies were excluded, because only a few estimates for single cancer sites existed. Hence, comparisons between regions or employment start were not feasible. When several articles provided risk measurements for the same study, only those with the broadest scope were included. For this reason, the results of four publications were not included in this meta-analysis (Firth et al. [@CR26]; Giles et al. [@CR28]; Heyer et al. [@CR36]; Rosénstock et al. [@CR61]). In total, 25 cohort studies were included in the meta-analysis (Fig. [1](#Fig1){ref-type="fig"}). We report only on cancer types which have been reported by more than one study and for male professional full-time firefighters. Cancer types were converted from earlier versions of the International Classification of Diseases (ICD) to the tenth revision (ICD-10). If appropriate, we additionally calculated estimates for all ICD-10 codes of a specific site combined, but also present the results for single ICD codes.Fig. 1PRISMA flowchart of literature search for cancer in firefighters

Statistics {#Sec4}
----------

The meta-relative risk estimates (mRRs) were assessed with inverse-variance random-effects meta-analyses with Paule--Mandel heterogeneity variance estimator *τ*^2^ and presented with the according 95% confidence intervals (CI) (Paule and Mandel [@CR55]; Veroniki et al. [@CR65]). Greater values of *τ*^2^ depict stronger between-study variances. If *τ*^2^ = 0, the mRRs are equal to the fixed-effects estimates. For the distinction between the mRRs of different estimates, we denote mRRs based on SIRs and SMRs as mSIRs and mSMRs. The percentage of variation across studies resulting from heterogeneity rather than chance were assessed with the *I*^2^ statistic (Higgins and Thompson [@CR37]). Heterogeneity testing based on Cochran's *Q*. *Q* is distributed as a Chi-square statistic with *k* − 1 degrees of freedom (*k* describing the number of studies). The hypothesis of homogeneity among studies would be rejected if *Q* exceeds $\documentclass[12pt]{minimal}
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                \begin{document}$$\chi_{k - 1\alpha }^{2}$$\end{document}$. The potential for publication bias was graphically explored through funnel plots and tested with the modified regression test (Lin and Chu [@CR45]). All statistical analyses were undertaken using SAS, version 9.4 (SAS Institute Inc., Cary, NC, USA).

Subgroups reported in this analysis were defined as follows: cohort studies with employment starting before 1950 were classified as "old", studies starting between 1950 and 1970 were classified as "medium", and later than 31th December 1970 studies were classified as "new". Studies located in the United States or Canada were summarized in the North America group. Studies from South Korea, Australia, and New Zealand were combined in the KOR/AUS/NZL group. The third group comprises studies from Europe, mainly from Scandinavia. Overall meta-analyses were only performed for cancer types which have been reported by more than one study. Subgroup analyses were done if data for more than one stratum existed and if cancer types have been reported by more than one study in at least one stratum. mRRs of single cancer types stratified by employment time or region were only presented in the main text if meaningful differences existed. Otherwise, results are presented in supplemental tables.

Results {#Sec5}
=======

Overall, 25 articles of cohort studies were included in this meta-analysis of those 56% presenting a cancer mortality (SMR), 28% a cancer incidence outcome (SIR), and 16% both estimates (Table [1](#Tab1){ref-type="table"}). Reported study populations were from six different countries in Europe, North America, South Korea, Australia, and New Zealand, but were mainly conducted in the United States and Canada (52% of articles). An overview of the extracted estimates from those 25 cohort studies is displayed in Supplemental Table S2.Table 1Characteristics of included cohort studies on firefighting and cancer riskStudy IDReferencesLocationOutcomeStudy periodFire fightersSample baseEmploymentFollow-up1Ahn et al. ([@CR2])KoreaIncidence1980--20071992--200729,438Registry2Ahn and Jeong ([@CR1])KoreaMortality1980--20071992--200729,453Registry3Amadeo et al. ([@CR4])FranceMortality1979--20081979--200810,829Registry4Aronson et al. ([@CR5])CanadaMortality19501950--19895373Fire department5Baris et al. ([@CR10])USAMortality1925--19861925--19867789Fire department6Bates et al. ([@CR11])New ZealandIncidence, mortality1977--19951977--19964221Registry7Berg and Howell ([@CR12])USAMortality1950195039 deathsDeath certificate8Daniels et al. ([@CR21])USAIncidence, mortality1950--20091950--200929,002Registry9Demers et al. ([@CR23])USAMortality1944--19791945--19894546Fire department10Demers et al. ([@CR22])USAIncidence1944--19791974--19892447Population11Deschamps et al. ([@CR24])FranceMortality1977--19911977--1991830Registry12Eliopulos et al. ([@CR25])AustraliaMortality1939--19781939--1978990Registry13Glass et al. ([@CR29])AustraliaIncidence, mortality1976--2003-201017,394Registry14Guidotti ([@CR32])CanadaMortality1927--1987-19873328Fire department15Hansen ([@CR34])DenmarkMortality1970--19801970--1980886Registry16Kullberg et al. ([@CR41])SwedenIncidence1931--19831958--20121080Registry17Ma et al. ([@CR46])USAMortality1972--19991972--199934,796Registry18Ma et al. ([@CR47])USAIncidence1981--19991981--199934,796Registry19Mastromatteo ([@CR49])CanadaMortality1921--19531921--19531500Fire department20Morton and Marjanovic ([@CR52])USAIncidence1963--19771963--19774 casesHospital21Musk et al. ([@CR53])USAMortality1915--19751915--19755655Registry22Petersen et al. ([@CR57])SwedenIncidence1968--20141968--20144,243Registry23Pukkala et al. ([@CR58])Northern EuropeIncidence1961--20051961--200516,422Registry24Tornling et al. ([@CR63])SwedenMortality1931--19831958--19861116Registry25Vena and Fiedler ([@CR64])USAMortality1950--19791961--20051867Death certificate/registry

Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}, and Supplemental Table S3 summarize the overall meta-analysis results of cancer risks of male professional firefighters from cohort studies for cancer incidence and mortality. The overall cancer mSIR of firefighters was similar to the general population and did not show a secular trend (Fig. [2](#Fig2){ref-type="fig"}). For individual cancers, we observed statistically significant elevated mSIR estimates for mesothelioma (mSIR = 1.46, 95% CI 1.01--1.90), bladder cancer (C67--C68 combined: mSIR = 1.14, 95% CI 1.04--1.23; C67: mSIR = 1.18, 95% CI 1.01--1.34), and colon cancer (mSIR = 1.11, 95% CI 1.00--1.21). We did not observe a secular trend for these cancer types. However, increased incidence risks over time exist for malignant melanoma of the skin, overall skin cancer, prostate, and testis cancer. The mSIR for stomach cancer was elevated in firefighters in the earliest employment period starting before 1950 (mSIR = 1.75, 95% CI 1.31--2.19, Supplemental Table S4) and decreases afterwards. In addition, a statistically significant reduced mSIR was observed for trachea and lung cancer in the period of employment starting after 1970. The mSIR of liver and brain cancer among firefighters was slightly lower than expected especially in the time of later employment. Other cancer sites were analyzed by only very few studies or showing no association with start of employment (Supplemental Table S4, Supplemental Fig. S1 and S2).Table 2Meta-relative risk estimates for cancer incidenceDisease (ICD-10)\# StudiesStudy IDsmSIR (95% CI)*I*^2^ (*p* value)*τ*^2^All cancer (C00--C97)91, 6, 8, 10, 13, 16, 18, 22, 231.00 (0.93--1.07)91.3 (\< 0.001)0.010Buccal cavity and pharynx (C00--C14)410, 13, 18, 230.87 (0.72--1.02)41.8 (0.161)0.003Lip (C00)216, 230.84 (0.43--1.25)0 (0.494)0Esophagus (C15)81, 6, 8, 10, 13, 16, 18, 231.06 (0.76--1.36)65.7 (0.005)0.088Stomach (C16)81, 6, 8, 10, 13, 16, 18, 231.08 (0.80--1.35)71.1 (0.001)0.109Small intestine (C17)21, 231.65 (0.40--2.90)2.2 (0.312)0.568Colon (C18)66, 10, 13, 16, 18, 23**1.11 (1.00--1.21)**19.6 (0.285)0Colorectal combined (C18--C21)51, 10, 13, 22, 231.08 (1.00--1.16)0 (0.539)0Rectum combined (C19--C21)86, 8, 10, 13, 16, 18, 22, 231.09 (0.99--1.19)0 (0.819)0Liver and biliary passages (C22--C24)31, 16, 230.90 (0.74--1.06)0 (0.377)0Liver (C22)41, 13, 18, 23**0.81 (0.65--0.98)**16.6 (0.309)0Gall bladder (C23, C24)21, 231.16 (0.55--1.78)40.2 (0.196)0.100Pancreas (C25)81, 6, 10, 13, 16, 18, 22, 231.08 (0.88--1.28)39.8 (0.114)0.021Larynx (C32)51, 10, 13, 18, 230.88 (0.66--1.10)0 (0.550)0Trachea and lung combined (C33--C34)81, 6, 8, 10, 13, 16, 18, 230.91 (0.78--1.03)87.7 (\< 0.001)0Bone (C40, C41)21, 181.38 (0.47--2.28)0 (0.438)0.086Skin combined (C43--C44)76, 10, 13, 16, 18, 22, 231.16 (0.98--1.35)74.2 (0.001)0.042Malignant melanoma of skin (C43)66, 10, 13, 16, 22, 231.19 (0.89--1.48)78.8 (\< 0.001)0.090Other malignant skin neoplasms (C44)416, 18, 22, 231.10 (0.90--1.30)63.2 (0.043)0.026Mesothelioma (C45)213, 23**1.46 (1.01--1.90)**0 (0.739)0Soft tissue (C48, C49)216, 231.20 (0.73--1.67)0 (0.699)0Breast (C50)48, 10, 13, 181.23 (0.27--2.19)28.6 (0.240)0.513Genitourinary system (C60--C68)28, 131.09 (0.99--1.18)57.3 (0.126)0.003Male genital (C60--C63)28, 131.10 (0.92--1.28)85.5 (0.009)0.016Prostate (C61)91, 6, 8, 10, 13, 16, 18, 22, 231.10 (0.97--1.22)75.0 (\< 0.001)0.025Testis (C62)56, 13, 18, 22, 231.26 (0.87--1.65)77.0 (0.002)0.141Urinary tract (C64--C68)38, 10, 131.07 (0.92--1.22)41.4 (0.182)0.007Kidney combined (C64--C66)81, 6, 8, 10, 13, 16, 18, 230.98 (0.75--1.20)62.6 (0.009)0.053Bladder combined (C67--C68)71, 6, 8, 10, 13, 18, 22**1.14 (1.04--1.23)**0 (0.592)0Bladder (C67)61, 6, 10, 13, 18, 22**1.18 (1.01--1.34)**0 (0.492)0.005Eye (C69)28, 183.08 (0.00--6.62)0 (0.461)5.255Brain combined (C70--C72)71, 6, 10, 13, 16, 18, 23**0.81 (0.65--0.98)**6.2 (0.380)0Thyroid (C73)51, 10, 13, 18, 231.26 (0.98--1.54)0 (0.623)0.011Lymphohematopoietic (C81--C96)41, 13, 16, 180.90 (0.63--1.17)76.1 (0.006)0.055Hodgkin\'s disease (C81)410, 13, 16, 180.84 (0.44--1.24)0 (0.906)0Non-Hodgkin lymphoma combined (C82--C85)61, 10, 13, 16, 18, 221.05 (0.83--1.28)0 (0.484)0.018Multiple myeloma (C90)410, 13, 16, 231.11 (0.85--1.38)0 (0.888)0Leukemia (C91--C95)91, 6, 8, 10, 13, 16, 18, 20, 231.05 (0.66--1.45)35.4 (0.135)0.248Statistically significant results are marked in bold*Study IDs* IDs of included studies in this meta-analysis as depicted in Table [1](#Tab1){ref-type="table"}, *mSIR* meta-relative standardized incidence ratios assessed with an inverse-variance random-effects meta-analysis with Paule--Mandel heterogeneity variance estimator *τ*^2^, *CI* confidence interval, *p value p* value of heterogeneity testTable 3Meta-relative risk estimates for cancer mortalityDisease (ICD-10)\# StudiesStudy IDsmSMR (95% CI)*I*^2^ (*p* value)*τ*^2^All cancer (C00--C97)172, 3, 4, 5, 6, 8, 9, 11, 12, 13, 14, 15, 17, 19, 21, 24, 250.97 (0.89--1.05)92.1 (\< 0.001)0.021Buccal cavity and pharynx (C00--C14)63, 5, 9, 11, 14, 170.97 (0.68--1.26)68.4 (0.007)0.044Digestive (C15--C26)411, 17, 21, 250.98 (0.71--1.24)61.1 (0.052)0.045Esophagus (C15)73, 4, 5, 8, 9, 17, 250.93 (0.64--1.23)73.3 (0.001)0.074Stomach (C16)112, 3, 4, 5, 6, 8, 9, 14, 17, 24, 250.94 (0.80--1.08)48.8 (0.034)0.009Colon (C18)83, 4, 5, 6, 9, 17, 24, 251.07 (0.78--1.35)67.2 (0.003)0.106Colorectal combined (C18--C21)42, 7, 9, 141.47 (0.52--2.42)86.5 (\< 0.001)0.869Rectum combined (C19--C21)93, 4, 5, 6, 8, 9, 17, 24, 25**1.35 (1.12--1.59)**0 (0.692)0.029Liver and biliary passages (C22--C24)35, 9, 250.95 (0.47--1.43)0 (0.790)0Liver (C22)52, 3, 4, 17, 240.84 (0.56--1.11)75.5 (0.003)0.035Pancreas (C25)83, 4, 5, 9, 14, 17, 24, 250.97 (0.73--1.22)54.9 (0.030)0.041Respiratory (C30--C39)411, 12, 21, 250.90 (0.73--1.08)0 (0.933)0Larynx (C32)34, 5, 90.59 (0.06--1.12)0 (0.553)0Trachea and lung combined (C33--C34)112, 3, 4, 5, 6, 8, 9, 14, 15, 17, 240.98 (0.86--1.11)72.1 (\< 0.001)0.025Skin combined (C43--C44)73, 4, 5, 6, 9, 14, 170.87 (0.59--1.15)0 (0.927)0Skin (C43, C44)53, 5, 9, 14, 170.89 (0.59--1.19)0 (0.823)0Malignant melanoma of skin (C43)24, 60.69 (0--1.50)0 (0.888)0Breast (C50)33, 8, 173.08 (0--7.15)10.5 (0.327)11.926Genitourinary system (C60--C68)38, 11, 211.29 (0.23--2.35)9.6 (0.331)0.668Prostate (C61)93, 4, 5, 8, 9, 14, 17, 24, 251.04 (0.86--1.22)54.8 (0.024)0.028Testis (C62)24, 81.46 (0--3.18)35.6 (0.213)1.060Urinary tract (C64--C68)28, 90.72 (0--1.57)97.0 (\< 0.001)0.345Kidney combined (C64--C66)83, 4, 5, 8, 9, 14, 24, 251.18 (0.42--1.94)76.1 (\< 0.001)1.008Bladder combined (C67--C68)93, 4, 5, 6, 8, 9, 14, 17, 251.44 (0.82--2.06)74.4 (\< 0.001)0.673Bladder (C67)73, 4, 5, 6, 14, 17, 25**1.72 (1.05--2.38)**45.6 (0.088)0.528Brain combined (C70--C72)94, 5, 6, 9, 14, 17, 21, 24, 251.42 (0.90--1.93)61.3 (0.008)0.418Lymphohematopoietic (C81--C96)72, 3, 6, 17, 21, 24, 25**0.76 (0.61--0.91)**0 (0.425)0Hodgkin's disease (C81)34, 9, 170.54 (0--1.18)54.8 (0.109)0Non-Hodgkin lymphoma combined (C82--C85)44, 5, 9, 171.31 (0.92--1.70)0 (0.446)0Multiple myeloma (C90)24, 51.12 (0--2.37)75.7 (0.042)0.555Leukemia combined (C91--C95, C91, C92)62, 4, 5, 8, 9, 171.04 (0.88--1.19)0 (0.459)0Statistically significant results are marked in bold*Study IDs* IDs of included studies in this meta-analysis as depicted in Table [1](#Tab1){ref-type="table"}, *mSMR* meta-relative standardized mortality ratios assessed with an inverse-variance random-effects meta-analysis with Paule--Mandel heterogeneity variance estimator *τ*^2^, *CI* confidence interval, *p value p* value of heterogeneity testFig. 2Secular trends of standardized incidence ratios of selected cancer types presented with 95% confidence intervals

The overall cancer mSMR of firefighters was similar to the general population, but decreased over time (employment start ≤ 1970: mSMR = 1.063, 95% CI 0.9--1.13 versus employment start \> 1970: mSMR = 0.81, 95% CI 0.70--0.92), as shown in Fig. [3](#Fig3){ref-type="fig"}. Overall, mSMRs were increased for rectal cancer (C19--C21 combined) and bladder cancer (C67) but not when considering malignant neoplasms of bladder together with other/unspecified urinary organs (C67--C68 combined). The mSMRs for rectal and brain cancer were increased especially in studies with employment starting between 1950 and 1970. Reduced but not always statistically significant mSMRs were observed for stomach, liver, trachea and lung, prostate, and brain cancer in the period of later employment. For stomach, liver, as well as trachea and lung cancer, findings were consistent across study types revealing a decreasing mSMR with later employment. However, the mSIR of prostate cancer increased over time, whereas its mSMR decreased.Fig. 3Secular trends of standardized mortality ratios of selected cancer types presented with 95% confidence intervals

Table [4](#Tab4){ref-type="table"} depicts the mSIR and mSMR results for selected cancer types stratified by region. The bladder mSIRs (C67 and C67--C68) were statistically significant in USA/Canada but not in Europe or KOR/AUS/NZL. In KOR/AUS/NZL, the estimates for malignant melanoma of the skin (mSIR = 1.43, 95% CI 1.27--1.58), prostate cancer (mSIR = 1.23, 95% CI 1.11--1.34), and testis cancer (mSIR = 1.47, 95% CI 1.10--1.83) were elevated. The mSIR of pancreas cancer was statistically significant increased only in Europe (mSIR = 1.23, 95% CI 1.01--1.45). In contrast, lung cancer mSIR was reduced in KOR/AUS/NZL (mSIR = 0.83, 95% CI 0.68--0.98). Overall, mSMR were decreased in KOR/AUS/NZL studies (mSMR = 0.78, 95% CI 0.59--0.97) in comparison to studies from North America (mSMR = 1.03, 95% CI 0.94--1.12). In addition to the increased bladder cancer mSIRs in North American studies, we only observed an increased SMR for bladder cancer (C67) but not for cancer of the bladder and other/unspecified urinary organs (C67-C68) in North American studies. The mSMR of pancreas or prostate cancer did not differ between regions, but stomach as well as trachea and lung cancer mSMRs were lowest in studies from KOR/AUS/NZL. Overall, lymphohematopoietic cancer SMR was lower than expected in all studies, but more pronounced in studies from North America. There were no meaningful differences between study regions for other cancer types (Supplemental Table S5). Heterogeneity is present between the studies. Especially studies with higher standard error will tend to report SIR or SMR more extreme for overall cancer (Supplemental Fig. S3).Table 4Meta-analysis results of selected cancer types for cancer incidence and mortality stratified by regionDisease (ICD-10 code)Region\# StudiesStudy IDsmRR (95% CI)*I*^2^ (*p* value)*τ*^2^Cancer incidence All cancer (C00--C97)Overall91, 6, 8, 10, 13, 16, 18, 22, 231.00 (0.93--1.07)91.3 (\< 0.001)0.010USA + Canada38, 10, 181.01 (0.84--1.18)96.9 (\< 0.001)0.021Europe316, 22, 230.98 (0.82--1.14)90.7 (\< 0.001)0.018KOR/AUS/NZL31, 6, 131.02 (0.94--1.10)58.7 (0.089)0.003 Stomach (C16)Overall81, 6, 8, 10, 13, 16, 18, 231.08 (0.80--1.35)71.1 (0.001)0.109USA + Canada38, 10, 180.98 (0.46--1.50)87.9 (\< 0.001)0.156Europe216, 231.45 (0.67--2.23)74.6 (0.047)0.281KOR/AUS/NZL31, 6, 130.93 (0.77--1.10)0 (0.894)0 Pancreas (C25)Overall81, 6, 10, 13, 16, 18, 22, 231.08 (0.88--1.28)39.8 (0.114)0.021USA + Canada210, 18,0.71 (0.25--1.18)48.9 (0.162)0.029Europe316, 22, 23**1.23 (1.01--1.45)**0 (0.530)0.005KOR/AUS/NZL31, 6, 131.05 (0.71--1.39)0 (0.908)0 Trachea and lung combined (C33--C34)Overall81, 6, 8, 10, 13, 16, 18, 230.91 (0.78--1.03)87.7 (\< 0.001)0USA + Canada38, 10, 180.93 (0.63--1.23)95.5 (\< 0.001)0.062Europe216, 230.95 (0.85--1.06)22.9 (0.255)0KOR/AUS/NZL31, 6, 13**0.83 (0.68--0.98)**0 (0.417)0 Skin combined (C43--C44)Overall76, 10, 13, 16, 18, 22, 231.16 (0.98--1.35)74.2 (0.001)0.042USA + Canada210, 181.17 (0.97--1.38)0 (0.947)0Europe316, 22, 231.02 (0.67--1.36)85.6 (0.001)0.079KOR/AUS/NZL26, 13**1.43 (1.27--1.58)**0 (0.571)0 Malignant melanoma of skin (C43)Overall66, 10, 13, 16, 22, 231.19 (0.89--1.48)78.8 (\< 0.001)0.090USA + Canada1101.20 (0.60--2.30)----Europe316, 22, 231.00 (0.40--1.60)89.6 (\< 0.001)0.237KOR/AUS/NZL26, 13**1.43 (1.27--1.58)**0 (0.571)0 Prostate (C61)Overall91, 6, 8, 10, 13, 16, 18, 22, 231.10 (0.97--1.22)75.0 (\< 0.001)0.025USA + Canada38, 10, 181.14 (0.93--1.35)62.2 (0.071)0.027Europe316, 22, 230.99 (0.70--1.27)90.1 (\< 0.001)0.057KOR/AUS/NZL31, 6, 13**1.23 (1.11--1.34)**0 (0.903)0 Testis (C62)Overall56, 13, 18, 22, 231.26 (0.87--1.65)77.0 (0.002)0.141USA + Canada118**1.60 (1.20--2.09)**Europe222, 230.87 (0.17--1.58)86.4 (0.007)0.204KOR/AUS/NZL26, 13**1.47 (1.10--1.83)**0 (0.865)0 Bladder combined (C67--C68)Overall71, 6, 8, 10, 13, 18, 22**1.14 (1.04--1.23)**0 (0.592)0USA + Canada38, 10, 18**1.14 (1.04--1.25)**0 (0.577)0Europe1221.14 (0.89--1.48)----KOR/AUS/NZL31, 6, 131.15 (0.69--1.61)36.9 (0.205)0.075Cancer mortality All cancer (C00--C97)Overall172--6, 8, 9, 11--15, 17, 19, 21, 24, 250.97 (0.89--1.05)92.1 (\< 0.001)0.021USA + Canada94, 5, 8, 9, 14, 17, 19, 21, 251.03 (0.94--1.12)88.7 (\< 0.001)0.014Europe43, 11, 15, 240.96 (0.90--1.02)0 (0.741)0KOR/AUS/NZL42, 6, 12, 13**0.78 (0.59--0.97)**87.9 (\< 0.001)0.025 Stomach (C16)Overall112--6, 8, 9, 14, 17, 24, 250.94 (0.80--1.08)48.8 (0.034)0.009USA + Canada74, 5, 8, 9, 14, 17, 251.00 (0.86--1.15)30.7 (0.193)0Europe23, 241.17 (0.84--1.50)0 (0.888)0KOR/AUS/NZL22, 6**0.65 (0.39--0.91)**0 (0.335)0 Rectum combined (C19--C21)Overall93--6, 8, 9, 17, 24, 25**1.35 (1.12--1.59)**0 (0.692)0.029USA + Canada64, 5, 8, 9, 17, 251.31 (0.99--1.62)0 (0.441)0.061Europe23, 241.58 (0.94--2.22)0 (0.454)0.094KOR/AUS/NZL161.21 (0.30--3.10)---- Pancreas (C25)Overall83--5, 9, 14, 17, 24, 250.97 (0.73--1.22)54.9 (0.030)0.041USA + Canada64, 5, 9, 14, 17, 250.90 (0.60--1.21)55.0 (0.049)0.054Europe23, 241.20 (0.89--1.52)0 (0.350)0KOR/AUS/NZL0-------- Lung combined (C33--C34)Overall112--6, 8, 9, 14, 15, 17, 240.98 (0.86--1.11)72.1 (\< 0.001)0.025USA + Canada64, 5, 8, 9, 14, 171.05 (0.95--1.15)43.3 (0.117)0.007Europe33, 15, 240.99 (0.61--1.36)10.3 (0.328)0.063KOR/AUS/NZL22, 6**0.64 (0.38--0.90)**30.9 (0.229)0 Prostate (C61)Overall93--5, 8, 9, 14, 17, 24, 251.04 (0.86--1.22)54.8 (0.024)0.028USA + Canada74, 5, 8, 9, 14, 17, 251.08 (0.97--1.18)0 (0.703)0Europe23, 240.83 (0.18--1.49)82.6 (0.016)0.165KOR/AUS/NZL0-------- Bladder combined (C67--C68)Overall93--6, 8, 9, 14, 17, 251.44 (0.82--2.06)74.4 (\< 0.001)0.673USA + Canada74, 5, 8, 9, 14, 17, 251.50 (0.78--2.21)79.2 (\< 0.001)0.752Europe130.73 (0.41--1.21)----KOR/AUS/NZL162.73 (0.30--9.80)---- Bladder (C67)Overall73--6, 14, 17, 25**1.72 (1.05--2.38)**45.6 (0.088)0.528USA + Canada54, 5, 14, 17, 25**1.88 (1.16--2.59)**0 (0.574)0.437Europe130.73 (0.41--1.21)----KOR/AUS/NZL162.73 (0.30--9.80)---- Lymphohematopoietic (C81--C96)Overall72, 3, 6, 17, 21, 24, 25**0.76 (0.61--0.91)**0 (0.425)0USA + Canada317, 21, 25**0.70 (0.50--0.90)**0 (0.494)0Europe23, 240.80 (0.45--1.15)66.9 (0.082)0.018KOR/AUS/NZL22, 60.86 (0.44--1.28)0 (0.632)0Statistically significant results are marked in bold*Study IDs* IDs of included studies in this meta-analysis as depicted in Table [1](#Tab1){ref-type="table"}, *mRR* meta-relative risk estimates (cancer incidence: standardized incidence ratios; cancer mortality: standardized mortality ratios) assessed with an inverse-variance random-effects meta-analysis with Paule--Mandel heterogeneity variance estimator *τ*^2^, *CI* confidence interval, *p value p* value of heterogeneity test

Discussion {#Sec6}
==========

This is the first meta-analysis exploring region-specific differences and secular trends. High heterogeneity was present in the previous meta-analyses that may be explained by these factors. We included the most recently published cohort studies on cancer risks of male professional firefighters by a systematic literature search to compare cancer risks among firefighters from different decades and different geographic areas.

Period of employment has been investigated as confounder according to cancer risks among firefighters in single-cohort studies before (Guidotti [@CR32]; Baris et al. [@CR10]; Kullberg et al. [@CR41]; Petersen et al. [@CR57]; Vena and Fiedler [@CR64]), but was not yet subject of a meta-analysis. Here, we observed a decline of the overall cancer mSMR in the employment period greater than 1970. In accordance with a cohort study of Danish firefighters we also found an increased pancreas cancer mSIR when employment started before 1970 (mSIR = 1.22, 95% CI 1.03--1.41 vs. single study SIR = 1.63, 95% CI 1.08--2.48) in comparison to later periods (Petersen et al. [@CR57]). An increased mSMR for bladder cancer (C67), especially in earlier employment periods, is in line with some other cohort studies (Baris et al. [@CR10]; Guidotti [@CR32]; Vena and Fiedler [@CR64]). On the other hand, the changing estimates over time for malignant melanoma of the skin, prostate, testis, stomach, and lung cancer in this meta-analysis were not observed before (Baris et al. [@CR10]; Kullberg et al. [@CR41]; Petersen et al. [@CR57]). We saw no elevated overall cancer mSIR in firefighters, so this meta-analysis could not confirm the reported trend of lower overall cancer incidence among firefighters employed in later periods (Kullberg et al. [@CR41]). This might be due to the specific characteristic of that cohort study by Kullberg et al.'s finding generally very low SIRs lying outside the funnel plot of this meta-analysis (Supplemental Fig. S3).

Our results for prostate cancer with estimates for mSIR and mSMR, showing in opposed directions over time, are plausible. Prostate cancer is the second most common malignancy in men worldwide and the sixth most leading cause of cancer death (Baade et al. [@CR9]). With the advent of Prostate-specific antigen (PSA) testing in the mid-late 1980 in the United States and other Western countries, more prostate cancers are diagnosed (Baade et al. [@CR9]). Special screening programs for firefighters and a higher awareness of potential risks as shown in the World Trade Center Health Registry cohort (Yung et al. [@CR69]) may result in additional PSA testing and, hence, more diagnosed prostate cancers in comparison to the general population. On the other hand, mortality rates decrease especially in developed countries because of earlier diagnosis due to PSA testing and improved treatment (Baade et al. [@CR9]). In this meta-analysis, geographical differences in prostate cancer mSIRs might be an incidental finding, because the KOR/AUS/NZL studies presenting SIRs for prostate cancer examined only firefighters employed after the mid-1970s.

Occupational exposure as a firefighter has been classified as possibly carcinogenic to humans by IARC with strongest evidence not only on the basis of prostate cancer but also because of testicular cancer (International Agency for Research on Cancer (IARC) [@CR39]). In accordance with earlier meta-analyses (Jalilian et al. [@CR40]; LeMasters et al. [@CR44]), we found an elevated mSIR for testicular cancer being more pronounced in studies with a later period of employment. The incidence rate of testicular cancer has increased especially in Western countries since the middle of the twentieth century (Manecksha and Fitzpatrick [@CR48]). Because testicular cancer occurs among younger men with high survival, mortality studies are less relevant (Manecksha and Fitzpatrick [@CR48]).

In the recent past, general preventive medical checkups lead to higher incidence rates of malignant melanoma of the skin as this is true for prostate cancer (Brunssen et al. [@CR16]). Again, special screening programs for firefighters and higher participation rates may result in more diagnosed melanomas in comparison to the general population as we can see in this meta-analysis and as it has been shown before (Jalilian et al. [@CR40]; LeMasters et al. [@CR44]). However, the increased mSIR has not been accompanied by a corresponding increase in mSMR which is in line with data from the United States (National Cancer Institute [@CR54]). We also found higher incidence rates of malignant melanoma of the skin in studies from Australia and New Zealand (mSIR = 1.43, 95% CI 1.27--1.58) in comparison to studies conducted in other countries (mSIR = 1.05, 95% CI 0.62--1.49) which might be rather caused by exposure to strong sunlight than occupational exposure as a firefighter (Leiter and Garbe [@CR43]).

Although lung cancer is the leading cause of cancer related deaths worldwide (Youlden et al. [@CR68]), earlier meta-analyses did not find any association between firefighting and lung cancer (Jalilian et al. [@CR40]; LeMasters et al. [@CR44]). Just a recent cohort of US firefighters from San Francisco, Chicago, and Philadelphia reported increased lung cancer morbidity and mortality risks (Daniels et al. [@CR21]). In general, the study by Daniels et al. reported higher SIRs and SMRs than the other studies and lying outside the funnel plots (Supplemental Fig. S3). However, the firefighters in the above-mentioned study were older at end of follow-up (mean age 60 years) than in the other studies which might have also contributed to these findings. Furthermore, the rather younger age of firefighters in the later studies might have caused the statistically significant deficit in trachea and lung cancer incidence (mSIR = 0.76, 95% CI 0.62--0.91).

In accordance with the latest meta-analysis, we did not find an overall association of stomach cancer and firefighting (Jalilian et al. [@CR40]). However, stomach cancer was more common than expected in studies with a start of employment before 1950 which is in line with a more detailed analysis in Swedish firefighters (Tornling et al. [@CR63]). Stomach cancer has been linked to several occupational exposures, such as working in the rubber manufacturing industry, mining industry, and agricultural industry, as well as exposure to crystalline silica, hexavalent chromium, asbestos, lead compounds, and nitrate (Raj et al. [@CR59]; Blair and Freeman [@CR13]; Lee et al. [@CR42]; Welling et al. [@CR66]; Cogliano et al. [@CR19]). Firefighters could be exposed to those compounds if the fire site holds these materials. Furthermore, "dusty occupations" could be related to stomach cancer (Raj et al. [@CR59]) which might also apply to firefighters who get in contact with dust for example during overhaul. However, the numbers were small with 35 observed stomach cancer cases in the strata of the early employment start.

We revealed lower overall and stomach cancer mSMRs in KOR/AUS/NZL than the United States and Canada. However, studies from KOR/AUS/NZL were conducted in later periods of employment with 80% representing a start of employment after 1970 in comparison to 23% of North American studies. Hence, the difference in mSMRs between regions may result from an actual decline of the overall cancer mortality with later period of employment.

Overall, mSIR and mSMR of bladder cancer (C67) were higher than expected. We did not observe any considerable secular trend but again lower estimates in studies from other countries, in comparison to studies from North America. However, just two non-American studies reported bladder cancer mortality risks. Hence, the risk was driven by the USA/Canada studies. In contrast to the incidence studies, the mortality studies are heterogeneous, but, here, we found the highest risk for all cancer entities. Firefighters are exposed to carcinogens associated with combustion, including polycyclic aromatic hydrocarbons, which represent an important risk factor of bladder cancer (International Agency for Research on Cancer (IARC) [@CR39]). Possible different exposure patterns depending on work activities and PPE may have caused such findings.

The limitations of the epidemiological data have to be acknowledged as well. Some of the studies examined relatively small populations of firefighters and thus have low statistical power to analyze especially rare cancer types. Additionally, the low number of eligible studies and different published diagnosis codes for cancer types (e.g., kidney cancer coded as C64, C64--C65, or C64--C66) and individually published combination of ICD codes \[e.g., brain cancer (C70--C72) together with malignant neoplasm of peripheral nerves of head, face, and neck (C47) (Daniels et al. [@CR21])\] complicate the analysis and contribute to low number of studies for each cancer type, especially after stratification by employment period and region. Therefore, it cannot be ruled out that risks will change after new studies will be published. Some studies analyzed incidence and mortality over several decades, which lead to uncertainties in the evaluation of trends in diagnosis, differences in exposure, and changes in PPE over time. Furthermore, the length of follow-up might contribute to biased findings. Especially in cohorts of younger firefighters, too short follow-up times might prevent to observe cancers associated with older age. In addition, the reader should have in mind that comparing SIRs or SMRs between groups is difficult if their confounder distributions differ (Checkoway et al. [@CR18]). In general, publications and data from other regions are missing, e.g., Southern Europe, Asia, and South and Central America. Finally, smoking habits and other risk factors were not available in these studies.

In contrast to population-based case--control studies, it is unlikely that cohort studies were missed during the literature search which has been recently published in a letter to the editor (Casjens et al. [@CR17]). The firefighter's population of cohort studies is well defined, and this will lead to a better estimation of potential risks and lesser bias. Additionally, instead of the commonly used DerSimonian--Laird estimator, we used in this meta-analysis the estimator proposed by Paule and Mandel being a better alternative to estimate the between-study variance (Veroniki et al. [@CR65]).

In this meta-analysis of 25 cohort studies of firefighters, the overall summary relative risk estimates were rather moderate with the exception of bladder cancer mortality. However, our results suggested differences of cancer mSIRs and mSMRs over time and between regions.

Conclusion {#Sec7}
==========

There are secular trends and region-specific differences in the relative risks of some cancer sites of male professional firefighters. The risk estimates are rather moderate and mostly declining over time. The introduction of innovative firefighting techniques, safer PPE, better communications, and information systems, as well as changes in the awareness of hazards have provided a safer and healthier working environment for firefighters over time leading to a reduction of overall cancer SIR and SMR. The increase of general preventive medical checkups and possible additional screenings for firefighters might have led to higher rate of diagnosed prostate cancer and malignant melanoma of the skin in the recent past. However, further efforts must be made to make the job as a firefighter even safer.
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